EC Approves Padcev + Keytruda for Resectable Muscle-Invasive Bladder Cancer: A Major Shift in Bladder Cancer Care

For patients diagnosed with muscle-invasive bladder cancer, surgery is often performed with curative intent. But for many patients, the journey does not end with surgery.

The risk of recurrence can remain high. For those who cannot receive cisplatin-based chemotherapy, treatment options before and after surgery have historically been limited.

That is why the latest European regulatory approval is important.

The European Commission has granted Marketing Authorization for Padcev (enfortumab vedotin) in combination with Keytruda (pembrolizumab) as a perioperative treatment for adults with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-containing chemotherapy.

The treatment is administered before radical cystectomy as neoadjuvant therapy and then continued after surgery as adjuvant therapy. It is now the first approved perioperative treatment option in the European Union for this specific patient group.

EC Approval of Padcev + Keytruda: Key Facts

What Is Muscle-Invasive Bladder Cancer?

Muscle-invasive bladder cancer, commonly called MIBC, is a form of bladder cancer in which the tumour has grown into the muscle layer of the bladder wall.

It is more serious than non-muscle-invasive bladder cancer because it has a greater risk of spreading beyond the bladder.

For many patients, the standard curative-intent approach involves radical cystectomy, a surgery that removes the bladder. In some cases, chemotherapy may be used before surgery to reduce the risk of recurrence and improve outcomes.

However, not every patient can receive cisplatin-based chemotherapy.

Some patients may be ineligible because of kidney function, hearing problems, neuropathy, frailty, heart-related concerns, or other medical factors. Others may decline cisplatin-based treatment after discussing risks and benefits with their oncology team.

For these patients, surgery alone has often been the primary treatment route.

The Padcev-Keytruda approval changes that treatment landscape in Europe.

What Does Perioperative Treatment Mean?

Perioperative treatment means therapy given around the time of surgery.

In this approval, the Padcev-Keytruda combination is used in two stages:

1. Neoadjuvant treatment — given before radical cystectomy

2. Adjuvant treatment — continued after surgery

The goal is to reduce cancer burden before surgery and lower the risk of recurrence after surgery.

This is especially important in MIBC, where patients may undergo major surgery but still face a meaningful risk of the disease returning.

Why This EC Approval Is Significant

This approval is significant because it establishes the first approved perioperative treatment option in the EU for patients with resectable MIBC who cannot receive cisplatin-containing chemotherapy.

The combination brings together two distinct oncology approaches:

• Padcev, an antibody-drug conjugate

• Keytruda, a PD-1 immune checkpoint inhibitor

This is also the first approved PD-1 inhibitor plus antibody-drug conjugate regimen in the EU for this cisplatin-ineligible resectable MIBC population.

For patients, it offers a treatment option beyond surgery alone.

For oncologists, it introduces a new evidence-based perioperative strategy.

For the pharmaceutical industry, it highlights the continued movement of advanced oncology combinations into earlier-stage and potentially curative-intent treatment settings.

Understanding Padcev and Keytruda

What Is Padcev?

Padcev, also known as enfortumab vedotin, is an antibody-drug conjugate, or ADC.

An ADC is designed to combine targeted delivery with anti-cancer activity.

Padcev targets Nectin-4, a protein commonly found on the surface of urothelial cancer cells. Once it binds to the cancer cell, it delivers a cytotoxic payload intended to damage and kill the tumour cell.

What Is Keytruda?

Keytruda, also known as pembrolizumab, is a PD-1 inhibitor.

PD-1 is a checkpoint pathway that can reduce the immune system’s ability to recognize and attack cancer cells.

By blocking PD-1, pembrolizumab is designed to help restore anti-tumour immune activity.

Why Use the Combination?

The scientific logic behind the combination is that Padcev directly targets tumour cells, while Keytruda supports the immune system’s ability to respond to cancer.

The combination has already been used in advanced urothelial cancer. This European Commission decision expands its use into earlier-stage, resectable muscle-invasive bladder cancer for eligible cisplatin-ineligible patients.

The EV-303 / KEYNOTE-905 Trial Results

The EC approval is based on the Phase 3 KEYNOTE-905 / EV-303 clinical trial.

The trial evaluated perioperative Padcev plus Keytruda compared with surgery alone in patients with previously untreated resectable MIBC who were ineligible for or declined cisplatin-containing chemotherapy.

The results showed clinically meaningful benefits.

Key Efficacy Findings

• The combination reduced the risk of recurrence, progression, or death by 60% compared with surgery alone.

• The hazard ratio for event-free survival was 0.40.

• Median event-free survival was not reached in the combination group, compared with 15.7 months for surgery alone.

• The combination reduced the risk of death by 50% compared with surgery alone.

• Median overall survival was not reached in the combination group, compared with 41.7 months for surgery alone.

• Pathologic complete response was 57.1% with the combination versus 8.6% with surgery alone.

These results are particularly meaningful because they show benefit in a patient population that has historically had limited perioperative treatment choices.

What Is Event-Free Survival?

Event-free survival, or EFS, measures how long patients live without certain negative outcomes occurring.

In the EV-303 trial, an event could include:

• Cancer recurrence

• Disease progression

• Death

A 60% reduction in the risk of an event does not mean every patient will experience the same outcome. However, it indicates a substantial difference between the combination treatment group and the surgery-alone group within the trial.

Safety Profile of Padcev + Keytruda

According to the approval announcement, the safety profile of the combination was consistent with the known profiles of the individual medicines.

No new safety signals were observed in the trial.

The most common treatment-related adverse events reported in at least 30% of patients included:

• Pruritus or itching

• Alopecia or hair loss

• Diarrhea

• Fatigue

• Anemia

Cancer treatment decisions should always be made by qualified oncology teams. Each patient’s treatment plan depends on factors such as cancer stage, overall health, kidney function, prior medical history, potential risks, expected benefits, and personal preferences.

Why Cisplatin-Ineligible Patients Need More Options

Cisplatin-based chemotherapy has long been a key treatment approach in bladder cancer.

But cisplatin is not suitable for every patient.

Up to half of patients with MIBC may be unable to receive cisplatin-containing chemotherapy, according to the information shared by Astellas.

Before this approval, many cisplatin-ineligible patients with resectable MIBC had no approved perioperative treatment option beyond surgery.

The Padcev-Keytruda combination provides a new pathway for this group, moving treatment beyond the traditional surgery-alone model.

Bladder Cancer Burden in Europe

Bladder cancer remains a major healthcare challenge across Europe.

Nearly 200,000 people are diagnosed with bladder cancer each year across the region, according to Astellas. Muscle-invasive disease accounts for up to 30% of bladder cancer cases.

MIBC carries a substantial risk of recurrence even after radical cystectomy.

This is why the approval is more than a product milestone. It reflects the growing need for treatment strategies that can improve outcomes before and after surgery.

A Shift From Advanced Disease to Curative-Intent Treatment

Padcev plus Keytruda was already approved in Europe for first-line treatment of certain patients with unresectable or metastatic urothelial cancer.

The new approval moves the combination into an earlier disease setting.

This is a major strategic shift in oncology.

Many cancer medicines first demonstrate value in advanced disease. Over time, if clinical evidence supports it, they may move into earlier lines of therapy, adjuvant treatment, neoadjuvant treatment, or perioperative treatment.

Earlier use can potentially improve long-term outcomes by addressing disease before it has spread or recurred.

The EC approval for Padcev plus Keytruda is a clear example of this treatment evolution.

What This Means for the Oncology Pharma Industry

This approval reinforces several important oncology trends:

1. Antibody-Drug Conjugates Are Becoming Central to Oncology Pipelines

ADCs are now among the most closely watched categories in oncology drug development.

They are designed to deliver cancer-killing agents more selectively to tumour cells, which may improve treatment precision.

2. Combination Therapy Is Becoming the New Standard

Modern oncology increasingly relies on combinations of:

• Immunotherapy

• Antibody-drug conjugates

• Targeted therapy

• Chemotherapy

• Radiation therapy

• Surgery

The Padcev-Keytruda regimen demonstrates how an ADC and an immune checkpoint inhibitor can work together in a curative-intent setting.

3. Clinical Trials Are Moving Into Earlier Cancer Stages

Pharma companies are no longer focusing only on metastatic disease.

More trials are exploring whether new combinations can improve outcomes before and after surgery.

4. Regulatory Strategy Is Expanding Beyond Single-Drug Approvals

Approvals involving complex treatment pathways require strong coordination across clinical development, regulatory affairs, medical affairs, pharmacovigilance, market access, and patient-support functions.

Career Opportunities Created by Oncology Innovation

Major oncology approvals often create demand across the pharmaceutical and life-sciences ecosystem.

Professionals may find growing opportunities in:

• Oncology Clinical Research

• Clinical Trial Operations

• Regulatory Affairs

• Medical Affairs

• Pharmacovigilance

• Medical Writing

• Biostatistics

• Clinical Data Management

• Oncology Sales and Marketing

• Market Access

• Health Economics and Outcomes Research

• Patient Support Programs

• Biologics Manufacturing

• Quality Assurance

• Oncology Commercial Excellence

For pharma professionals in India, global oncology approvals can create downstream opportunities through multinational pharma companies, clinical research organizations, global capability centers, pharmacovigilance teams, regulatory consulting firms, and scientific communication agencies.

What Happens Next?

Following European Commission approval, Astellas and its partners will work with regulatory authorities, reimbursement agencies, and health technology assessment bodies across EU markets.

The next steps may include:

• Country-level reimbursement discussions

• Local pricing and access decisions

• Oncology centre education

• Treatment guideline updates

• Medical affairs and scientific communication initiatives

• Post-marketing safety monitoring

• Real-world evidence collection

Patient access timelines may vary across countries depending on national reimbursement and healthcare-system decisions.

Key Takeaways

• The European Commission has approved Padcev plus Keytruda for adults with resectable muscle-invasive bladder cancer who are ineligible for cisplatin chemotherapy.

• The regimen is used before and after radical cystectomy as perioperative treatment.

• It is the first approved perioperative treatment option in the EU for this patient population.

• The approval is based on the Phase 3 KEYNOTE-905 / EV-303 trial.

• The combination reduced the risk of recurrence, progression, or death by 60% compared with surgery alone.

• It reduced the risk of death by 50% compared with surgery alone.

• The approval expands Padcev and Keytruda from advanced urothelial cancer into an earlier, curative-intent setting.

• The milestone highlights continued growth in antibody-drug conjugates, immunotherapy combinations, and perioperative oncology treatment strategies.

About BIG PHARMA JOBS

BIG PHARMA JOBS, powered by BIG IDEAS HR Consulting Pvt. Ltd., connects pharmaceutical and life-sciences professionals with opportunities across India.

With 16+ years of pharmaceutical recruitment expertise, 25,000+ successful placements, and partnerships with 1,000+ pharma companies, BIG PHARMA JOBS helps candidates stay informed about the global drug approvals, oncology breakthroughs, regulatory updates, and career trends shaping the future of pharma.

Explore current opportunities in Clinical Research, Regulatory Affairs, Medical Affairs, Pharmacovigilance, Quality Assurance, Biologics Manufacturing, and Oncology-focused roles through BIG PHARMA JOBS.